BMS Earnings Beat Estimates, But Opdivo Sales Slide Continues

 
• By Mandy Jackson

The company believes the PD-1 inhibitor’s recent declines will be reversed through new indications, providing revenue growth along with other new products by the time Revlimid faces generics in 2022.

Financial Report
Opdivo sales have declined, but are expected to rise in 2021

More from Earnings

More from Business